Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-blind study of patiromer for the treatment of hyperkalemia
2012-001956-20Phase 3Completed
- Sponsor
- Relypsa, Inc.
- Start
- Dec 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, single-blind, single-arm trial of patiromer in hyperkalemia and chronic kidney disease (CKD), sponsored by Relypsa, Inc. Primary endpoint: Change in serum potassium (Part A). Started Dec 2012; status: completed.
02
Drugs
patiromer
03
Conditions
hyperkalemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-001956-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001956-20.